Assenagon Asset Management S.A. Trims Holdings in Edwards Lifesciences Corporation $EW

Assenagon Asset Management S.A. reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 44.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,265,714 shares of the medical research company’s stock after selling 1,020,584 shares during the period. Assenagon Asset Management S.A.’s holdings in Edwards Lifesciences were worth $101,358,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp lifted its stake in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after buying an additional 371,892 shares during the period. Wellington Management Group LLP boosted its position in Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after acquiring an additional 989,533 shares during the last quarter. Norges Bank purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $803,686,000. Morgan Stanley raised its holdings in Edwards Lifesciences by 12.4% in the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after acquiring an additional 804,942 shares during the last quarter. Finally, Marshall Wace LLP raised its holdings in Edwards Lifesciences by 66.1% in the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Up 3.0%

Shares of EW opened at $89.56 on Thursday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $51.57 billion, a P/E ratio of 47.64, a price-to-earnings-growth ratio of 2.18 and a beta of 0.87. The stock’s fifty day simple moving average is $83.93 and its 200 day simple moving average is $83.18. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $90.99.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the business earned $0.64 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on EW shares. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Finally, Evercore reaffirmed an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a research note on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.